PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).
Lauren C. Harshman(Dana-Farber Cancer Institute), Anil Kapoor(People’s University), Michael A.S. Jewett(Princess Margaret Cancer Centre), Brian Shuch(University of California, Los Angeles), Mohamad E. Allaf(Johns Hopkins University), M. Dror Michaelson(Harvard University), Charles G. Drake(Columbia University Irving Medical Center), Eliezer M. Van Allen(Dana-Farber Cancer Institute), David Cella(Northwestern University), Naomi B. Haas(University of Pennsylvania), Sabina Signoretti(Brigham and Women's Hospital), Daniel J. George(Duke University), Toni K. Choueiri(Harvard University), Mäneka Puligandla(Dana-Farber Cancer Institute), Primo N. Lara(UC Davis Comprehensive Cancer Center), Lynne I. Wagner(University of North Carolina at Chapel Hill), Rajan T. Gupta(Duke University), David F. McDermott(Beth Israel Deaconess Medical Center), Michael A. Carducci(Sidney Kimmel Comprehensive Cancer Center), Daniel Yick Chin Heng(University of Calgary)
Cited by 1
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008
|Journal of Clinical Epidemiology|2010|5.1k